Alpha Tau Medical (NASDAQ:DRTS) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Alpha Tau Medical (NASDAQ:DRTS) to a sell rating in a research note published on Saturday morning.

A number of other equities analysts have also recently issued reports on DRTS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Alpha Tau Medical in a research note on Wednesday, October 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $9.00.

Alpha Tau Medical Price Performance

DRTS opened at $4.16 on Friday. The stock has a 50-day moving average price of $3.92 and a 200-day moving average price of $3.31. Alpha Tau Medical has a 12-month low of $2.14 and a 12-month high of $4.69. The company has a current ratio of 10.52, a quick ratio of 5.81 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $352.85 million, a P/E ratio of -8.67 and a beta of 1.07.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). Equities analysts predict that Alpha Tau Medical will post -0.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alpha Tau Medical

An institutional investor recently bought a new position in Alpha Tau Medical stock. XTX Topco Ltd bought a new stake in Alpha Tau Medical Ltd. (NASDAQ:DRTS) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 21,195 shares of the company’s stock, valued at approximately $53,000. 2.65% of the stock is currently owned by institutional investors.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.